MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc., a company developing protein and antibody therapeutics, presented findings at IBC Life Sciences’ 17th Annual Antibody Engineering Conference demonstrating the effects of XmAb™5871, a humanized anti-CD19 antibody therapeutic, in suppressing autoimmunity through B-cell inhibition without depleting B cells, a novel mechanism created using Xencor’s Fc engineering technology.
